Patents Assigned to The United States of America as represented by the Secretary of Health & Human Services
-
Patent number: 12012438Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.Type: GrantFiled: June 14, 2021Date of Patent: June 18, 2024Assignee: The United States of America, as represented by the Secretary, Health and Human ServicesInventors: Jeffrey Schlom, Claudia M. Palena
-
Patent number: 11617753Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.Type: GrantFiled: November 6, 2017Date of Patent: April 4, 2023Assignees: OYAGEN, INC., The United States of America, as represented by the Secretary of Health and Human ServicesInventors: Harold C. Smith, Ryan P. Bennett, Peter Jahrling
-
Patent number: 10730835Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: September 29, 2016Date of Patent: August 4, 2020Assignees: The United States of America, as represented by the Secretary, Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10501528Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: June 20, 2016Date of Patent: December 10, 2019Assignees: V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Patent number: 10053514Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.Type: GrantFiled: July 9, 2014Date of Patent: August 21, 2018Assignees: Duke University, The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
-
Publication number: 20180185309Abstract: Provided are compositions and methods for improving podocyte and kidney function and glucose homeostasis in diabetic and pre-diabetic states.Type: ApplicationFiled: June 2, 2016Publication date: July 5, 2018Applicants: The Regents of the University of California, United States of America, as Represented by Secretary of Health and Human ServicesInventors: Bruce D. HAMMOCK, Fawaz G. HAJ, Ahmed BETTAIEB, Darryl C. Zeldin
-
Patent number: 9676788Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).Type: GrantFiled: February 5, 2015Date of Patent: June 13, 2017Assignees: The United States of America, as represented by the Secretary of Health and Human Services, University of HawaiiInventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
-
Patent number: 9492564Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: GrantFiled: May 6, 2014Date of Patent: November 15, 2016Assignees: Duke University, The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Peagram
-
Patent number: 9441048Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: GrantFiled: November 15, 2011Date of Patent: September 13, 2016Assignees: The United States of America as represented by the Secretary of Health and Human Services, Duke UniversityInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Patent number: 9408901Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: November 8, 2013Date of Patent: August 9, 2016Assignees: TAKEDA VACCINES, INC, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH & HUMAN SERVICESInventors: Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Patent number: 8445216Abstract: The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.Type: GrantFiled: October 18, 2011Date of Patent: May 21, 2013Assignees: Duke University, The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Chien-Tsun Kuan, Darell D Bigner, Ira H Pastan
-
Patent number: 8268890Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: GrantFiled: December 30, 2008Date of Patent: September 18, 2012Assignees: Johns Hopkins University, The United States of America as represented by the Secretary of Health and Human Services, The Regents of the University of CaliforniaInventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Patent number: 8101380Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.Type: GrantFiled: March 21, 2008Date of Patent: January 24, 2012Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Daniel R. Weinberger, Stephen J. Huffaker, Joel E. Kleinman, Bai Lu
-
Patent number: 8039593Abstract: The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.Type: GrantFiled: October 31, 2006Date of Patent: October 18, 2011Assignees: Duke University, The United States of America as represented by the Secretary of Health and Human ServicesInventors: Chien-Tsun Kuan, Darell D Bigner, Ira H Pastan
-
Publication number: 20110201035Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virs infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: August 18, 2011Applicant: The United States of America as Represented by the Secretary of Health and Human Services, NIHInventors: Hana Golding, Surender Khurana
-
Patent number: 7854899Abstract: A method for preparing a microarray that includes placing at least one template over a first surface of the recipient block, wherein the template defines an array of openings and the recipient block has a plurality of receptacle holes, such that the array of openings are aligned with the plurality of receptacle holes. A needle or punch that contains a sample is inserted through the openings of the template. The sample then is inserted into the receptacle hole in the recipient block. A device is also disclosed that includes a platform defining (i) a first surface, and (ii) a first region configured to retain at least one recipient block; and a raised template defining an array of openings, secured to the first surface of the platform and positioned above the first region configured to retain the recipient block.Type: GrantFiled: August 26, 2004Date of Patent: December 21, 2010Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventor: Stephen M. Hewitt
-
Patent number: 7815916Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.Type: GrantFiled: June 5, 1995Date of Patent: October 19, 2010Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Nancy T. Chang, Robert C. Gallo, Flossie Wong-Staal
-
Publication number: 20090270265Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.Type: ApplicationFiled: July 27, 2007Publication date: October 29, 2009Applicants: The United States of America as Represented by the Secretary of Health and Human Services, Genzyme Corporation, The Johns Hopkins University School of MedicineInventors: Mariana NACHT, Tatiana Dracheva, David Sidransky, Stephen Madden, Jin Jen
-
Patent number: 7570986Abstract: A computer-assisted method for detecting surface features in a virtual colonoscopy. The method includes providing a three-dimensional construction of a computed tomography colonography surface; creating a path along the teniae coli from the proximal ascending colon to the distal descending colon on the colonography surface; forming an indexed computed tomography colonography surface using the created path; and registering the supine and prone scans of the computed tomography colonography surface using the indexed computed tomography colonography surface. The method also includes navigating the internal surface of the computed tomography colonography using the indexed computed tomography colonography surface.Type: GrantFiled: May 17, 2006Date of Patent: August 4, 2009Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Hui-Yang Huang, Dave A. Roy, Ronald M. Summers
-
Patent number: 7517849Abstract: ATP-binding cassette (ABC) transporters generally contain a number of transmembrane helices. The present invention provides synthetic peptides derived from these transmembrane helices. The peptides inhibit ABC transporter function, presumably by disrupting the structure of the ABC transporter. Negatively charged residues are added at the extracellular terminus to promote correct orientation of the peptide in the membrane, and residues considered to aid solubility may be added at that terminus to increase solubility. Exemplary ABC transporters that can be inhibited by these peptides include MDR1, MRP1, MRP2 and BCRP. The invention further provides nucleic acids encoding the peptides, expression cassettes comprising the nucleic acids, and host cells expressing the expression cassettes. The invention further provides a simple and inexpensive assay for determining whether a potential chemotherapeutic agent can inhibit the activity of P-gly-coprotein.Type: GrantFiled: November 17, 2000Date of Patent: April 14, 2009Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Nadya I. Tarasova, Christopher J. Michejda, Michael M. Gottesman, Christine A. Hrycyna